A New England Journal of Medicine trial shows perioperative durvalumab plus enfortumab vedotin significantly improves overall survival in cisplatin-ineligible bladder cancer.
Most Recent Articles
Nature Medicine Study Demonstrates 3D Skeletal Motion Encodes Multisystem Health Markers Across 1,887 Phenotypes
A Nature Medicine study reveals that a gait foundation model analyzing 3D skeletal motion successfully predicts 1,887 multisystem health phenotypes across 18 body systems.
Circadian Misalignment Correlates with Increased Gut Permeability and Metabolic Inflammation in Obesity
An iScience study links late chronotypes and circadian misalignment to increased gut permeability, microbial dysbiosis, and systemic metabolic inflammation in adults with obesity.
Benchmarking Small Language Models for Spanish Clinical Text Simplification and Health Literacy
A Scientific Reports study establishes the MEDICLARO benchmark to evaluate small AI language models simplifying Spanish clinical reports into plain language.
JAMA Study Evaluates 11-Year Mortality Outcomes in Routine Invasive Versus Conservative Management of Chronic Coronary Disease
The JAMA ISCHEMIA-EXTEND trial shows early heart procedures provide no long-term survival benefit over medication in stable coronary disease.